Contract Research Organisation (Pre-Clinical)

Abstract

Over a period of time, drug discovery and development has become more costlier and riskier. The complexity of research has led to widening of the productivity gap, characterised by newer challenges and novel mechanisms of action. Globally 14 of the 55 blockbuster drugs are in licensed and in the next few years more than 20 percent of the global research spend would be on in licensing. Inspite of increased spending the number of new molecular entities approved each year by the Food and Drug Authority (FDA) has been on the decline.